Openbookopenbook
Equity
Sorrento Therape(SRNE)
USD --+0.00%
Reward60Moderate
Risk76High
📊75%Data
Revenue growing 31% YoY
SRNE
+0.0 · +0.00%
USD · OTCQB
Sorrento Therape | Healthcare
Profitless Growth
Market Cap:1.82M
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
76
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SRNE to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $13.00.

What is Sorrento Therape?

, a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally.

SRNE · Verdict

Solid reward · high risk

SRNE stands out on valuation and growth, but watch the cash flow signal.

Based on 88% data coverage

SRNE · Verdict

What’s working & what to watch

Strengths 2

  • Valuation89/100

    P/E 1.2×

  • Growth76/100

    Rev +26.0% CAGR · earnings +15.9%

Watchouts 4

  • Cash flow16/100

    -489% free-cash-flow margin

  • Profitability19/100

    -890% net margin · -379% ROE

  • Balance sheet23/100

    Current ratio 0.29

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Sorrento Therape?

, a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 1.82M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with valuation and growth as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.82M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.016
52 Week Low0.0002
Last AnnualDecember
IPO Date1/11/2010
IncorporatedUSA
Shares Outstanding551M
No. of Employees949
IndustryBiotechnology
ExchangeOTCQB
Beta1.463
CurrencyUSD
Websitewww.sorrentotherapeutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.